Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions

ObjectiveAmivantamab plus chemotherapy has been proved to be an efficient treatment strategy for non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions. The aim of this study was to conduct the cost-effectiveness analysis of amivantamab-chemotherapy compar...

Full description

Bibliographic Details
Main Authors: Ping Yue, Mengwei Zhang, Yuanying Feng, Yuan Gao, Chao Sun, Peng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
amivantamab
chemotherapy
cost-effectiveness analysis
non-small-cell lung cancer
papillon
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1368804/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1368804/full

Similar Items